• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Chromocell Corporation - Articles and news items


Astellas and Chromocell to develop neuropathic pain treatments

Industry news / 30 September 2015 / Victoria White

Astellas has obtained worldwide rights to commercialise Chromocell’s lead compound, CC8464 – an oral, peripherally-acting inhibitor of NaV1.7…


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +